Cover Image
市場調查報告書

搭配診斷 (CDx)的全球市場:2018年∼2028年

The Companion Diagnostics (CDx) Market Forecast 2018-2028: Leading Companies, Trends and Developments in the Growing Theranostics Market

出版商 Visiongain Ltd 商品編碼 210220
出版日期 內容資訊 英文 183 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
搭配診斷 (CDx)的全球市場:2018年∼2028年 The Companion Diagnostics (CDx) Market Forecast 2018-2028: Leading Companies, Trends and Developments in the Growing Theranostics Market
出版日期: 2018年04月10日 內容資訊: 英文 183 Pages
簡介

全球搭配診斷市場,2023年預計達到146億美元,到2028年記錄穩定的成長。這個市場成長的促進因素,是細胞及組織研究的進步,法規情形的改善,各地的政府援助的強化,未滿足的醫療需求領域發表了幾個新治療方法等。

本報告提供搭配診斷 (CDx)的全球市場的相關調查,個人化醫療及體外診斷檢驗 (IVD檢驗) 的搭配診斷的地位,搭配診斷的市場規模的變化與預測,搭配診斷之一的治療診斷的成長,主要國家趨勢,主要的已上市產品與開發平台的聯盟趨勢,搭配診斷發展的經營模式,競爭環境,主要企業簡介等彙整。

第1章 報告概要

第2章 搭配診斷:簡介

  • 個人化醫療基礎
  • 個人化醫療:患者治療範例的變化
  • 體外診斷檢驗 (IVD檢驗)
    • 搭配診斷:IVD的類型之一
    • 搭配診斷和治療診斷的差異
    • 生物標記和搭配診斷
    • 基因生物標誌物
    • 癌症的基因生物標誌物
  • 相關法律
  • 搭配診斷的同時期的開發的獎勵

第3章 全球搭配診斷市場

  • 範圍和限制
  • 全球搭配診斷市場:成果
  • 全球搭配診斷市場:銷售額預測
  • 超過搭配診斷:之外的IVD部門的成長
  • 搭配診斷:IVD市場上市場佔有率增加
  • 各部門市場成果
  • 治療診斷:搭配診斷中的最快成長部門
  • 搭配診斷的主要部門的佔有率的變化預測

第4章 搭配診斷:主要國家市場預測

  • 主要國家市場:主要3個市場主導的現狀
  • 主要國家的銷售額預測
    • 市場佔有率變化的預測
  • 美國的銷售額預測
  • 歐盟5國的成果
    • 銷售額預測
    • 佔有率的變化
    • 德國的銷售額預測
    • 法國的銷售額預測
    • 義大利的銷售額預測
    • 西班牙的銷售額預測
    • 英國的銷售額預測
  • 日本的銷售額預測
  • 中國的銷售額預測
  • 印度的銷售額預測
  • 巴西的銷售額預測
  • 俄羅斯的銷售額預測
  • 韓國的銷售額預測
  • 其他的銷售額預測

第5章 搭配診斷市場:已上市產品和開發平台的聯盟

  • 生物標記:搭配診劃分發的中心
  • 美國FDA核准完畢搭配診斷檢驗
  • 癌症的診斷:作為搭配診斷的研發產品線的對象仍為主流
  • 高額的癌症治療推動CDx的開發
  • 搭配診斷/製藥經營者的聯盟

第6章 搭配診斷:經營模式和相關利益者

  • 搭配診斷發展的經營模式
  • 進入搭配診斷市場的推動因素
  • 對搭配診斷市場有影響力的相關利益者
  • 搭配診斷市場上的競爭情形

第7章 主要企業

  • Roche:診斷市場全球的領導者
  • Qiagen N.V.:對製藥經營者來說的CDx的主要聯盟處
  • Abbott Molecular:確立的競爭經營者
  • Agilent Technologies (Dako)
  • Myriad Genetics
  • BioMerieux
  • Thermo Fisher Scientific

第8章 定量分析

  • SWOT分析
  • 優勢
  • 弱點
  • 機會
  • 威脅
  • 波特的五力分析

第9章 總論

  • 概要
  • 治療診斷:急速成長的市場
  • 搭配診斷的主要企業
  • 製藥/診斷公司的合作模式
  • 癌症是推動搭配診斷的主要治療領域
  • 搭配診斷市場商業性成長推動因素
  • 搭配診斷市場商業性阻礙成長要素
  • 彙整

第10章 詞彙表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: PHA0300

What can be expected from the Companion Diagnostics market? Which areas are going to grow at the fastest rates? This visiongain report shows you potential revenues to 2028, assessing data, trends, opportunities and prospects there.

Our 183-page report provides 127 tables, charts, and graphs. Discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales across the whole companion diagnostics market. You will see financial results, trends, opportunities, and revenue predictions. There is much opportunity in this fast moving market.

Forecasts from 2018-2028 and other analyses show you commercial prospects

Besides revenue forecasting to 2028, our new study provides you with recent results, growth rates, and market shares. Discover qualitative analyses (including SWOT and Porterús Five Forces analysis) and commercial developments.

The report also includes will find revenue forecasts to 2028 for the following submarkets in the companion diagnostics market:

  • Theranostics
  • Other Companion Diagnostics

Additionally, this report includes a forecast to 2026 for the global in vitro diagnostics market.

The report also includes will find revenue forecasts to 2028 for the following national and regional markets for companion diagnostics:

  • US
  • Germany
  • France
  • Italy
  • Spain
  • UK
  • Japan
  • China
  • India
  • Russia
  • Brazil
  • South Korea

image1

The report provides detailed profiles of key companies operating within the companion diagnostics market:

  • F. Hoffmann-La Roche Ltd
  • Qiagen N.V.
  • Abbott Laboratories
  • Agilent Technologies
  • Myriad Genetics
  • bioMerieux
  • Thermo Fisher Scientific

Leading companies and potential for market growth

Overall revenue for the Companion Diagnostics market will reach $14.60n in 2023, our work forecasts. We predict strong revenue growth through to 2028. Advances in cellular and tissue research, an improving regulatory landscape, strong support from governments in multiple regions and the launch of several new therapies in areas of unmet clinical need will drive sales to 2028.

Our work analyses the key companies in the market. See visiongainús analysis of 7 leading companies, including these:

  • F. Hoffmann-La Roche Ltd
  • Qiagen N.V.
  • Abbott Laboratories
  • Agilent Technologies
  • Myriad Genetics
  • bioMerieux
  • Thermo Fisher Scientific

A company profile gives you the following information where available:

  • Discussion of a companyús activities and outlook
  • Historic revenue, analysis and discussion of company performance over the past 5 years
  • Analysis of major products currently on the market
  • Acquisitions and strategic partnerships

Discover capabilities, progress, and commercial prospects, helping you stay ahead.

What issues will affect the companion diagnostics industry?

Our new report discusses issues and events affecting the companion diagnostics market. You will find discussions, including qualitative analyses:

  • Highly diverse market needing strong knowledge of key therapeutic indications
  • Changing regulatory landscape challenging new entrants and major market players alike
  • Emerging therapies with the potential to reshape the market

You will see discussions of technological, commercial, and economic matters, with emphasis on the competitive landscape and business outlooks.

How the Companion Diagnostics: Market Forecast 2018-2028 report helps you

In summary, our 183-page report gives you the following knowledge:

  • Revenue forecasts to 2028 for the Companion Diagnostics market - discover the industryús prospects, finding promising places for investments and revenues
  • Revenue forecasts to 2028 for each major submarket - discover prospects for leading companion diagnostics products in the following areas: theranostics and other companion diagnostics.
  • Revenue forecasts to 2028 for twelve leading national markets - US, Germany, France, Italy, Spain, UK, Japan, China, India, Russia, Brazil and South Korea
  • Assessment of 7 leading companies - analysis of products, revenue, mergers & acquisitions, sales by region and products
  • Discussion of what stimulates and restrains companies and the market
  • Prospects for established firms and those seeking to enter the market

You will find quantitative and qualitative analyses with independent predictions. You will receive information that only our report contains, staying informed with this invaluable business intelligence.

Information found nowhere else

With our survey you are less likely to fall behind in knowledge or miss opportunities. See how you could benefit your research, analyses, and decisions. Also see how you can save time and receive recognition for commercial insight.

Visiongainús study is for everybody needing commercial analyses for the companion diagnostics market and leading companies. You will find data, trends and predictions.

Table of Contents

1. Report Overview

  • 1.1 The Companion Diagnostics Market Overview
  • 1.2 Companion Diagnostics Market Segmentation
  • 1.3 Why You Should Read This Report
  • 1.4 How This Report Delivers
  • 1.5 Key Questions Answered by This Analytical Report
  • 1.6 Who is This Report For?
  • 1.7 Methodology
  • 1.8 Frequently Asked Questions (FAQ)
  • 1.9 Associated Reports
  • 1.10 About Visiongain

2. Introduction to Companion Diagnostics

  • 2.1 The Foundation of Personalised Medicine
  • 2.2 Personalised Medicine: Changing the Patient Treatment Paradigm
  • 2.3 In Vitro Diagnostic (IVD) Tests
    • 2.3.1 Companion Diagnostics: A Type of IVD
    • 2.3.2 Differences between Companion Diagnostics and Theranostics
    • 2.3.3 Biomarkers to Companion Diagnostics
    • 2.3.4 Genomic Biomarkers
    • 2.3.5 Genomic Oncology Biomarkers
  • 2.4 Regulations in the Companion Diagnostics Market
    • 2.4.1 FDA's Final Guidance on Companion Diagnostics
    • 2.4.2 LDTs: A Changing Landscape
  • 2.5 Encouraging the Contemporaneous Development of Companion Diagnostics

3. The World Companion Diagnostics Market, 2017-2028

  • 3.1 Scope and Limitations
  • 3.2 The Global Companion Diagnostics Market, 2016 and 2017
  • 3.3 The Global Companion Diagnostics Market Sales Forecast, 2017-2028
  • 3.4 Companion Diagnostics: Growth Outpacing the Rest of the IVD Market
  • 3.5 Companion Diagnostics: Increasing Market Share of the IVD Market
  • 3.6 The Companion Diagnostics Market by Submarket, 2017
  • 3.7 Theranostics: Fastest Growing Segment of the CDx Market
  • 3.8 Changing Market Shares of the Leading Companion Diagnostics Submarkets, 2017-2028

4. Leading National Markets for Companion Diagnostics, 2017-2028

  • 4.1 The Leading National Markets for Companion Diagnostics: Led by 3 Dominant Markets in 2017
  • 4.2 The Leading National Markets for Companion Diagnostics Sales Forecast, 2017-2028
    • 4.2.1 Changing Market Shares of Leading National Markets, 2017-2028
  • 4.3 The US Companion Diagnostics Market Sales Forecast, 2017-2028
    • 4.3.1 The US Will Continue to Dominate the Market
  • 4.4 The EU5 Companion Diagnostics Sales Market, 2017
    • 4.4.1 The EU5 Companion Diagnostics Market Sales Forecast, 2017-2028
    • 4.4.2 Changing Market Shares of the EU5 Companion Diagnostics Market
    • 4.4.3 The German Companion Diagnostics Market Sales Forecast 2017-2028
    • 4.4.4 The French Companion Diagnostics Market Sales Forecast, 2017-2028
    • 4.4.5 The Italian Companion Diagnostics Market Sales Forecast, 2017 2028
    • 4.4.6 The Spanish Companion Diagnostics Market Sales Forecast, 2017-2028
    • 4.4.7 The UK Companion Diagnostics Market Sales Forecast, 2017-2028
  • 4.5 The Japanese Companion Diagnostics Market Sales Forecast, 2017-2028
    • 4.5.1 Japanús Medical Technology Regulatory Process Reducing Time to Market
  • 4.6 The Chinese Companion Diagnostics Market Sales Forecast, 2017-2028
    • 4.6.1 Cancer Rates will Drive Adoption of Companion Diagnostic Tests
  • 4.7 The Indian Companion Diagnostics Market Sales Forecast, 2017-2028
  • 4.8 The Brazilian Companion Diagnostics Market Sales Forecast, 2017-2028
  • 4.9 The Russian Companion Diagnostics Market Sales Forecast, 2017-2028
  • 4.10 The South Korean Companion Diagnostics Market Sales Forecast, 2017-2028
  • 4.11 The Rest of the World Companion Diagnostics Market Sales Forecast, 2017-2028

5. The Companion Diagnostics Market: Marketed Products and Pipeline Partnerships

  • 5.1 Biomarkers: At the Forefront of Companion Diagnostics Development
  • 5.2 US FDA Approved Companion Diagnostic Tests, 2016
  • 5.3 Oncology Continues to Dominate the R&D Pipeline of Companion Diagnostics
  • 5.4 Expensive Cancer Therapies Encourages the Development of CDx
  • 5.5 Companion Diagnostic/Pharma Partnerships, 2013-2014

6. Business Models and Stakeholders in the Companion Diagnostics Market

  • 6.1 Business Models for the Development of Companion Diagnostics
    • 6.1.1 The Partnership Model is the Most Practiced Method
    • 6.1.2 The Stand-Alone Model: Licensing an IP
    • 6.1.3 The One Stop Shop Model: An Approach by Big Pharma
    • 6.1.4 Using Contract Diagnostics Organisations (CDO): An Emerging Trend
  • 6.2 Factors Driving Companies to Enter the Companion Diagnostics Market
  • 6.3 Stakeholders Influencing the Companion Diagnostics Market
    • 6.3.1 Pharmaceutical Companies and Diagnostic Manufacturers
    • 6.3.2 Regulatory Authorities
    • 6.3.3 Testing Laboratories
    • 6.3.4 Physicians and Patients
    • 6.3.5 Payers
  • 6.4 Companion Diagnostics Competitive Landscape, 2017

7. Leading Companies in the Companion Diagnostics Market 2017

  • 7.1 Roche: Global Diagnostics Leader
    • 7.1.1 Ventana Medical Systems (Roche)
    • 7.1.2 Sales and Recent Performance Analysis, 2016
    • 7.1.3 Roche Diagnostics by Region, 2016
    • 7.1.4 Roche: Growing Diagnostic Portfolio
    • 7.1.5 Approval of Ventana and Cobas EGFR Mutation Test V2
    • 7.1.6 Rocheús Portfolio of Companion Diagnostic Project Pipeline and Marketed Companion Diagnostics, 2017
    • 7.1.7 Ventana Companion Diagnostics: Robust New Prototype Assays
    • 7.1.8 Recent Companion Diagnostic External Collaborations, 2014-2017
      • 7.1.8.1 Roche/Ariosa Diagnostics and Signature Diagnostics
      • 7.1.8.2 Loxo Oncology/ Roche: Larotrectinib Pan-TRK IHC Companion Diagnostic
      • 7.1.8.3 CAPP Medical/ Roche: Development for Diagnostic Operating Segment
      • 7.1.8.4 GENEWEAVE and Kapa Acquisitions Help Cement Rocheús Position as the Market Leader
      • 7.1.8.5 Foundation Medicine/Roche
      • 7.1.8.6 MedImmune (AstraZeneca)/Ventana: Assay for NSCLC Targeted Clinical Trials
      • 7.1.8.7 Merck/Ventana: CDx for an Undisclosed Target
      • 7.1.8.8 AstraZeneca/Roche: CDx to Support Target Drug AZD9291
      • 7.1.8.9 Boehringer Ingelheim/Roche
      • 7.1.8.10 ImmunoGen/ Ventana
  • 7.2 Qiagen N.V.: Leading CDx Collaborator with Pharmaceutical Companies
    • 7.2.1 Sales and Recent Performance Analysis, 2012-2016
    • 7.2.2 Qiagen Sales by Region
    • 7.2.3 Qiagenús Portfolio of Marketed Companion Diagnostics, 2016
    • 7.2.4 Companion Diagnostics Collaboration Agreements with Pharma, 2016
      • 7.2.4.1 Collaboration with Therawis Diagnostics
      • 7.2.4.2 Collaboration with HTG Molecular Diagnostics
      • 7.2.4.3 Collaboration with Array BioPharma
      • 7.2.4.4 Collaboration with Singulex
      • 7.2.4.5 Strategic Acquisitions
  • 7.3 Abbott Molecular: An Established Competitor
    • 7.3.1 Sales and Recent Performance Analysis, 2014-2016
    • 7.3.2 Abbott Molecular: Expansive Oncology Biomarker Pipeline
    • 7.3.3 Recent Collaborations
      • 7.3.3.1 Collaboration with Celgene and Agios
      • 7.3.3.2 Collaboration with AstraZeneca
      • 7.3.3.3 Collaborative Efforts with Idera
  • 7.4 Agilent Technologies (Dako)
    • 7.4.1 Life Sciences and Diagnostics Business
    • 7.4.2 Agilent Life Sciences and Diagnostics, Sales and Recent Performance Analysis, 2016
    • 7.4.3 Agilent: Next Generation Sequencing Platforms
    • 7.4.4 Recent Companion Diagnostic Approvals
      • 7.4.4.1 Expanded FDA Approval for the Use of Dako PD-L1 IHC 22C3 pharmDx Companion Diagnostic in Gastric or Gastroesophageal Junction (GEJ) Cancer
      • 7.4.4.2 Agilent/ Bristol- Myers Squibbús: Companion Diagnostic Approvals
      • 7.4.4.3 Agilent/Pfizer/Merck: An Ongoing Collaboration
    • 7.4.5 Strategic Acquisitions
      • 7.4.5.1 Acquisition of i-Lab Solutions
      • 7.4.5.2 Acquisition of Multiplicom
  • 7.5 Myriad Genetics
    • 7.5.1 Acquisition of Myriad RBM: Increases the Companyús Market Share of Companion Diagnostics
    • 7.5.2 Companion Diagnostic Service Offerings
    • 7.5.3 Sales and Recent Performance Analysis, 2016
      • 7.5.3.1 myRisk: Next Generation Hereditary Cancer Testing
    • 7.5.4 Myriad Genetics Recent Collaborations
      • 7.5.4.1 Myriad/BeiGene: Collaboration Agreement
      • 7.5.4.2 Myriad/AstraZeneca: Complementary Diagnostic FDA Approvals
      • 7.5.4.3 Acquisition of /Sividone Diagnostics
      • 7.5.4.4 Acquisition of Assurex Health
      • 7.5.4.5 Collaboration with AbbVie
  • 7.6 BioMérieux
    • 7.6.1 Sales and Recent Performance Analysis, 2016
    • 7.6.2 Sales by Region, 2016
    • 7.6.3 Sales by Technology, 2016
    • 7.6.4 Companion Diagnostics: Recent M&A Activity & Collaboration
      • 7.6.4.1 Strategic Acquisitions
      • 7.6.4.2 Collaboration with Banyan Biomarkers
      • 7.6.4.3 Agreement with Astute Medical to Distribute Nephrocheck
      • 7.6.4.4 Mergers, Acquisitions and Collaborations
    • 7.6.5 bioTheranostics: Subsidiary for Oncology Diagnostics
  • 7.7 Thermo Fisher Scientific
    • 7.7.1 Sales and Recent Performance Analysis, 2014-2016
      • 7.7.1.1 Thermo Fisher Scientific Sales by Region, 2016
    • 7.7.2 Recent Collaborations and Acquisitions
      • 7.7.2.1 Thermo Fisher Scientific/Seegene-FDA Clearances
      • 7.7.2.2 Thermo Fisher Scientific/University Hospital Basel
      • 7.7.2.3 Acquisition of Alfa Aesar
      • 7.7.2.4 Affymetrix: Thermo Fisherús Next Target
      • 7.7.2.5 Thermo Fisher Scientific Collaboration with Pfizer and Novartis to Offer NGS-Based Companion Test for NSCLC

8. Qualitative Analysis of the Companion Diagnostics Market, 2017-2028

  • 8.1 SWOT Analysis of the Companion Diagnostics Market
  • 8.2 Strengths
    • 8.2.1 A CDx Strategy Decreases the Length of Approval Process
    • 8.2.2 Premium Prices for Companion Diagnostics
    • 8.2.3 A CDx Development Strategy Can Generate More Effective Drugs
    • 8.2.4 Therapeutics Tied with CDx can have Safer Profiles
    • 8.2.5 Reducing the Cost of Healthcare
    • 8.2.6 Increased Regulatory Scrutiny on Marketed Drugs
    • 8.2.7 Targeted Therapies Will Drive the CDx Market
  • 8.3 Weaknesses
    • 8.3.1 Reimbursement Challenges
    • 8.3.2 Lack of Clear Regulatory Guidelines
    • 8.3.3 Capital Intensity is High
  • 8.4 Opportunities
    • 8.4.1 Fast-growing Emerging Markets
    • 8.4.2 Next Generation Sequencing
    • 8.4.3 Many New CDx/ Pharma Company Partnerships
  • 8.5 Threats
    • 8.5.1 Complex Business Models and Business Partnerships
    • 8.5.2 Medical Device Excise Tax
  • 8.6 Porterús Five Forces Analysis of the Companion Diagnostics Market
    • 8.6.1 Rivalry Among Competitors [High]
    • 8.6.2 Power of Suppliers [High]
    • 8.6.3 Power of Buyers [Medium]
    • 8.6.4 Threat of New Entrants [Medium]
    • 8.6.5 Threat of Substitutes [High]

9. Conclusions

  • 9.1 Overview
  • 9.2 Theranostics: A Fast Growing Market
  • 9.3 Leading Companion Diagnostic Companies
  • 9.4 Pharmaceutical/Diagnostic Partnership Model
  • 9.5 Oncology is the Leading Therapy Area Driving Companion Diagnostics
  • 9.6 Commercial Drivers of the Companion Diagnostics Market
  • 9.7 Commercial Restraints of the Companion Diagnostics Market
  • 9.8 Concluding Remarks

10. Glossary

  • Associated Reports
  • Visiongion Report Sales Order Form
  • Appendix A
  • About Visiongain
  • Appendix B
  • Visiongain Report Evaluation Form

Table of Tables

  • Table 1.1 The CDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%) 2017-2023
  • Table 1.2 The CDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%) 2023-2028
  • Table 2.1 Examples of Clinically Relevant Cancer Biomarkers, 2016
  • Table 3.1 The World IVD Market: Revenue ($bn) and Market Share (%) by Segment, 2017
  • Table 3.2 The World CDx Market: Revenue ($bn), AGR (%) and CAGR (%), 2017-2023
  • Table 3.3 The World CDx Market: Revenue ($bn), AGR (%) and CAGR (%), 2023-2028
  • Table 3.4 The World IVD and CDx Market: Revenue ($bn), AGR (%) and CAGR (%), 2017-2023
  • Table 3.5 The World IVD and CDx Market: Revenue ($bn), AGR (%) and CAGR (%), 2023-2028
  • Table 3.6 CDx Market Share (%) in the IVD Market, 2017, 2023, 2028
  • Table 3.7 The World Companion Diagnostics Market: Revenue ($bn) and Market Share (%) by Submarket, 2017
  • Table 3.8 The World Companion Diagnostics Market by Submarket: Revenue ($bn), AGR (%) and CAGR (%), by Submarket, 2017-2023
  • Table 3.9 The World Companion Diagnostics Market by Submarket: Revenue ($bn), AGR (%) and CAGR (%), by Submarket, 2023-2028
  • Table 3.10 Revenue ($bn) and Market Share (%) of Submarkets in the CDx Market, 2017, 2023, 2028
  • Table 4.1 The Leading National Markets for CDx: Sales ($m), Market Share (%), 2017
  • Table 4.2 The Leading National Companion Diagnostics Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2017-2023
  • Table 4.3 The Leading National Companion Diagnostics Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2023-2028
  • Table 4.4 Revenue ($bn) and Market Share (%) of the National Markets in the CDx Market, 2017, 2023, 2027
  • Table 4.5 The US CDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%) 2017-2023
  • Table 4.6 The US CDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%) 2023-2028
  • Table 4.7 The EU5 CDx Market Forecast: Revenue ($bn) and Market Share (%), 2017
  • Table 4.8 The EU5 Companion Diagnostic National Market Forecasts: Revenue ($bn), AGR (%) and CAGR (%), 2017-2023
  • Table 4.9 The EU5 Companion Diagnostic National Market Forecasts: Revenues ($bn), AGR (%) and CAGR (%), 2023-2028
  • Table 4.10 Market Share (%) of Each EU5 Region in the CDx Market, 2017, 2023, 2027
  • Table 4.11 The German CDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2017-2028
  • Table 4.12 The German CDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2017-2028
  • Table 4.13 The French CDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2017-2023
  • Table 4.14 The French CDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2023-2028
  • Table 4.15 The Italian CDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2017-2023
  • Table 4.16 The Italian CDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2023-2028
  • Table 4.17 The Spanish CDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2017-2023
  • Table 4.18 The Spanish CDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2023-2028
  • Table 4.19 The UK CDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2017-2023
  • Table 4.20 The UK CDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2023-2028
  • Table 4.21 The Japanese CDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%) 2017-2023
  • Table 4.22 The Japanese CDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%) 2023-2028
  • Table 4.23 The Chinese CDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2017-2023
  • Table 4.24 The Chinese CDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2023-2028
  • Table 4.25 The Indian CDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2017-2023
  • Table 4.26 The Indian CDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2023-2028
  • Table 4.27 The Brazilian CDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2017-2023
  • Table 4.28 The Brazilian CDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2027-2028
  • Table 4.29 The Russian CDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2017-2023
  • Table 4.30 The Russian CDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2023-2028
  • Table 4.31 The South Korean CDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2017-2023
  • Table 4.32 The South Korean CDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2023-2028
  • Table 4.33 The Rest of the World CDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2017-2023
  • Table 4.34 The Rest of the World CDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2023-2028
  • Table 5.1 List of FDA-Approved Drugs with Pharmacogenomic Biomarker Information in Their Labelling, 2018
  • Table 5.2 (Contúd) List of FDA-Approved Drugs with Pharmacogenomic Biomarker Information in Their Labelling, 2018
  • Table 5.3 (Contúd) List of FDA-Approved Drugs with Pharmacogenomic Biomarker Information in Their Labelling, 2018
  • Table 5.4 (Contúd) List of FDA-Approved Drugs with Pharmacogenomic Biomarker Information in Their Labelling, 2018
  • Table 5.5 (Contúd) List of FDA-Approved Drugs with Pharmacogenomic Biomarker Information in Their Labelling, 2018
  • Table 5.6 List of Cleared or Approved Companion Diagnostic Devices and Their Complementary Therapeutic Drug, 2015-2017
  • Table 5.7 List of CDx Diagnostic/Pharma Partnerships, 2015-2017
  • Table 6.1 List of Companies in the Companion Diagnostics Market, 2017
  • Table 6.2 (Contúd) List of Companies in the Companion Diagnostics Market, 2017
  • Table 7.1 Roche Diagnostics: Revenue ($bn) and Revenue Share (%) by Business Area, 2016
  • Table 7.2 Roche Diagnostics: Revenue ($bn), Revenue Shares (%) by Region, 2016
  • Table 7.3 Roche: Instruments/devices planned for 2017
  • Table 7.4 Roche: Tests/Assays planned for 2017
  • Table 7.5 Roche Diagnostics: List of Marketed Companion Diagnostics, 2017
  • Table 7.6 Qiagen: Revenue ($bn), Net Income ($bn) and Profit Margin, 2012-2016
  • Table 7.7 Qiagen: Revenue ($m), Revenue Share (%) by Geography, 2014-2016
  • Table 7.8 Qiagen: Marketed Molecular Diagnostic Products, 2016
  • Table 7.9 Qiagenús Molecular Diagnostics by Therapeutic Area, 2016
  • Table 7.10 Abbott: Revenue ($bn) by Segment, 2014-2016
  • Table 7.11 Abbott Molecular: Biomarker Pipeline, 2017
  • Table 7.12 Agilent Technologies: Revenue ($bn) by Business Segment 2014-2016
  • Table 7.13 Myriad Genetics: Biomarker Product Portfolio, 2016
  • Table 7.14 Myriad Genetics: Revenue ($bn) by Segment, FY ended June 2015- FY ended June 2017
  • Table 7.15 bioMérieux : Revenue (€bn), ($bn) and AGR (%), 2012-2016
  • Table 7.16 bioMérieux: Revenue Share (%) by Technology, 2016
  • Table 7.17 Thermo Fisher Scientific: Revenue ($bn) and Market Share (%)
  • Table 7.18 Thermo Fisher Scientific: Revenue ($bn), Revenue Share (%) by Geography, 2016
  • Table 8.1 SWOT Analysis of the Companion Diagnostics Market, 2017-2028
  • Table 9.1 Theranostics and Other In Vitro Diagnostics: Global Sales Forecast ($bn), 2017, 2023 and 2028

Table of Figures

  • Figure 1.1 Companion Diagnostics: Overview of Submarkets
  • Figure 2.1 Development of Biomarkers into Companion Diagnostics, 2018
  • Figure 3.1 The World IVD Market: Market Share (%) in the IVD Market, 2017
  • Figure 3.2 The World CDx Market: Revenue ($bn), AGR (%) and CAGR (%), 2017-2028
  • Figure 3.3 The World IVD and CDx Market: Revenue ($bn), AGR (%) and CAGR (%), 2017-2028
  • Figure 3.4 The World CDx Market Share (%) in the IVD Market, 2023
  • Figure 3.5 The World CDx Market Share (%) in the IVD Market, 2028
  • Figure 3.6 The World Companion Diagnostics Market: Market Share (%) by Submarket, 2017
  • Figure 3.7 The World CDx Market by Submarket: Revenue ($bn) and AGR (%) 2017-2028
  • Figure 3.8 The World CDx Market Share (%) in the IVD Market, 2023
  • Figure 3.9 The World CDx Market Share (%) in the IVD Market, 2028
  • Figure 4.1 The Leading National Markets for CDx by Sales ($bn), 2017
  • Figure 4.2 The Leading National Markets for CDx by Market Share (%), 2017
  • Figure 4.3 The Leading National Markets for CDx by Market Share (%), 2023
  • Figure 4.4 The Leading National Markets for CDx by Market Share (%), 2027
  • Figure 4.5 The US CDx Market Forecast: Revenue ($bn) and AGR (%), 2017-2028
  • Figure 4.6 The EU5 Leading National Markets for CDx by Revenue ($bn), 2017
  • Figure 4.7 The EU5 Leading National Markets for CDx by Market Share (%), 2017
  • Figure 4.8 The EU5 National Markets for CDx by Market Share (%), 2023
  • Figure 4.9 The EU5 National Markets for CDx by Market Share (%), 2028
  • Figure 4.10 The German CDx Market Forecast: Revenue ($bn) and AGR (%) 2017-2028
  • Figure 4.11 The French CDx Market Forecast: Revenue ($bn) and AGR (%) 2017-2028
  • Figure 4.12 The Italian CDx Market Forecast: Revenue ($bn) and AGR (%) 2017-2028
  • Figure 4.13 The Spanish CDx Market Forecast: Revenue ($bn) and AGR (%) 2017-2028
  • Figure 4.14 The UK CDx Market Forecast: Revenue ($bn) and AGR (%) 2017-2028
  • Figure 4.15 The Japanese CDx Market Forecast: Revenue ($bn) and AGR (%), 2017-2028
  • Figure 4.16 The Chinese CDx Market Forecast: Revenue ($bn) and AGR (%) 2017-2028
  • Figure 4.17 The Indian CDx Market Forecast: Revenue ($bn) and AGR (%) 2017-2028
  • Figure 4.18 The Brazilian CDx Market Forecast: Revenue ($bn) and AGR (%) 2017-2028
  • Figure 4.19 The Russian CDx Market Forecast: Revenue ($bn) and AGR (%) 2017-2028
  • Figure 4.20 The South Korean CDx Market Forecast: Revenue ($bn) and AGR (%) 2017-2028
  • Figure 4.21 The Rest of the World CDx Market Forecast: Revenue ($bn) and AGR (%) 2017-2028
  • Figure 6.1 Current Business Models for the Development of Companion Diagnostics, 2017
  • Figure 6.2 Stakeholders in the Companion Diagnostics Market, 2017
  • Figure 7.1 Roche Diagnostics: Revenues ($bn) by Business Area, 2016
  • Figure 7.2 Roche Diagnostics: Revenue Share (%) by Business Area, 2016
  • Figure 7.3 Roche Diagnostics: Revenue Share (%) by Geography, 2016
  • Figure 7.4 Qiagen: Revenue ($bn) and Net Income ($bn), 2012-2016
  • Figure 7.5 Qiagen: Revenue Share (%) by Geography, 2016
  • Figure 7.6 Abbott Laboratories: Historical Revenue ($bn), 2013-2016
  • Figure 7.7 Abbott Laboratories: Revenue Share (%) by Business Sector, 2016
  • Figure 7.8 Agilent Technologies: Revenue ($bn) by Business Segment 2014-2016
  • Figure 7.9 Myriad Genetics: Segment Share (%), 2016
  • Figure 7.10 bioMérieux: Revenue ($bn) and AGR (%), 2012-2016
  • Figure 7.11 bioMérieux: Revenue by Region (%), 2016
  • Figure 7.12 bioMérieux: Revenue Share (%) by Technology, 2015
  • Figure 7.13 Thermo Fisher Scientific: Revenue Sales (%) by Business Sector, 2016
  • Figure 7.14 Thermo Fisher Scientific: Revenue Share (%) by Geography, 2016
  • Figure 8.1 Drivers and Restraints in the Companion Diagnostics Market, 2017-2028
  • Figure 8.2 Porterús Five Analysis of the Companion Diagnostics Market, 2017-2028
  • Figure 9.1 Theranostics and Other In Vitro Diagnostics: World Sales Forecast ($bn), 2017, 2023 and 2028

Companies Listed

  • 20/20 Gene Systems
  • Abbott Diagnostics
  • Abbott Molecular
  • Affymetrix
  • Agilent (Dako)
  • Almac
  • Ambry Genetics
  • Amgen
  • Arca bipharma
  • Arno
  • Astellas Pharma
  • AstraZeneca
  • Asuragen
  • Bayer
  • Biogenex Laboratories, Inc.
  • bioMérieux
  • Biomonitor
  • Boehringer Ingelheim
  • Brain Resource Company
  • Bristol-Myers Squibb
  • Cancer Research UK
  • CancerGuide Diagnostics
  • Caprion Proteomics
  • Caris Life Sciences
  • Celera (acquired by Quest Diagnostics)
  • Celgene
  • Cepheid
  • ChemGenex Pharmaceuticals
  • Clarient
  • Clinical Reference Laboratory
  • Clovis
  • College of American Pathology (CAP)
  • CompanDx
  • Crescendo Bioscience
  • Curidium Medica
  • Dako (Agilent)
  • Deloitte
  • DiagnoCure
  • Dx assays
  • DxS
  • Eli Lilly
  • Endocyte
  • European Medicines Agency (EMA)
  • Exosome Diagnostics
  • Ferring
  • Flagship Biosciences
  • FlowMetric Diagnostics
  • Foundation Medical
  • Foundation Medicine
  • Genentech
  • Genfit
  • Genia Technologies
  • Genmab
  • GenMark Diagnostics
  • Gilead Sciences
  • GlaxoSmithKline
  • GSK
  • Hexie Health
  • HistologiX
  • Idera
  • Illumina
  • ImmunoGen
  • Incyte
  • InDex Pharmaceuticals
  • IntegraGen
  • Inverness Medical Innovations (now known as Alere)
  • Invivoscribe Technologies
  • Ipsen
  • Ipsogen
  • IQuum
  • Janssen Pharmaceutical
  • Kimball Genetics (a division of LabCorp)
  • Kunlun Health Insurance
  • Lab Corp
  • Lab21
  • Laboratory for Personalized Molecular Medicine
  • Leica
  • Leica Biosystems
  • Leica Micosystems
  • Life Technologies
  • Medical Research Council
  • Medicare
  • MedImmune (AstraZeneca)
  • Merck
  • Merck Serono
  • MolecularMD
  • Monogram Biosciences
  • Myriad Genetics
  • Myriad RBM
  • Nanosphere
  • Nanostring
  • NanoString Technologies
  • National Health Insurance (NHI) (South Korea)
  • NIH
  • Northern Institute for Cancer Research
  • Novartis
  • Oxford BioTherapeutics (earlier Oxford Genome Sciences)
  • Pacific Diagnostics Clinical Laboratory (ResearchDx)
  • Pfizer
  • PICC Health Insurance
  • Ping An Insurance Group
  • Prionics
  • Progenika Biopharma
  • Prometheus
  • Protagen
  • Protagen Diagnostics
  • Qiagen
  • Quintiles
  • Quintiles Transnational Corporation
  • Randox Pharma Services
  • ResearchDx
  • Resonance Health
  • Resonance Health Analysis Services
  • RiboMed Biotechnologies
  • Roche
  • Rule-Based Medicine
  • Saladax Biomedical
  • ServizioSanitarioNazionale (SSN)
  • Siemens
  • Siemens Healthcare
  • Signal Genetics
  • Sirius Genomics
  • Sistema Único de Saúde (SUS)
  • Skyline Diagnostics
  • Solvay Innogenetics
  • Sysmex Inostics
  • Takedaús Millennium unit
  • Target Discovery
  • TcLand Expression
  • TESARO
  • The Association of British Pharmaceutical Industries
  • The Food and Drug Administration (FDA)
  • The Haute Autorité de santé (HAS)
  • The National Institute for Health and Care Excellence (NICE)
  • Theranostics (NZ)
  • Theranostics Health
  • Thermo Fisher
  • Thermo Fisher Scientific
  • Third Wave Technologies (Hologic)
  • TIB MolBiol
  • Tocagen
  • Tragara Pharmaceuticals
  • Transgenomic
  • TRICARE
  • TrimGen Corporation
  • Tufts Center for the Study of Drug Development
  • Unilabs
  • University of Newcastle
  • Ventana Medical Systems (a subsidiary of Roche)
  • ViiV Healthcare
  • Weisenthal Cancer Group
Back to Top